Intestifalk (Budesonide)

Budesonide binds to glucocorticoid receptors inside cells, modulating gene transcription. This action suppresses pro‑inflammatory cytokines, limits immune cell migration, and stabilises cellular membranes, resulting in a potent anti‑inflammatory effect within the gastrointestinal tract.

The appropriate dosage of Intestifalk is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

The safety of budesonide in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Intestifalk delivers targeted glucocorticoid activity directly to the gut, often resulting in fewer systemic side effects compared with systemic steroids. Compared with mesalamine or biologics, budesonide provides rapid symptom control but may be used for milder disease or as induction therapy.

Intestifalk should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it out of direct sunlight to maintain stability.

Intestifalk is taken orally as directed by the prescriber, usually with water. The tablet or capsule should be swallowed whole and not chewed or crushed unless specifically instructed.

Serious risks include adrenal suppression, severe infections, hypersensitivity reactions such as anaphylaxis, perforated gastrointestinal ulcer, marked hyperglycemia, and long‑term bone loss leading to osteoporosis. Patients should be monitored for these events throughout therapy.

Intestifalk is contraindicated in patients with known hypersensitivity to budesonide or any excipients, those with active systemic infections, and individuals who have had recent gastrointestinal perforation or severe ulcer disease. Caution is also advised for patients with uncontrolled diabetes or osteoporosis.